Oslo University Hospital HF

Haematology and Cellular Immunotherapy

Research activity includes follicular lymphoma, multiple myeloma, acute lymphoblastic leukemia, lymphoblastic lymphoma, and graft-versus-host disease, with a strong interest in targeted immune-based treatment strategies and disease monitoring in blood cancers.

  • Follicular lymphoma
  • Multiple myeloma
  • Acute lymphoblastic leukemia
  • Graft-versus-host disease

Additional work spans minimal residual disease-guided treatment, CAR T-cell therapy, and vaccine-based immunotherapy in relapsed or high-risk haematological malignancies.

Solid Tumours and Precision Oncology

The sponsor is active in breast cancer, non-small cell lung cancer, glioblastoma, colorectal cancer, melanoma, esophageal cancer, pancreatic cancer, and malignant pleural mesothelioma, with emphasis on biomarker-informed treatment selection and tumour-directed immunotherapy.

  • Breast cancer
  • Non-small cell lung cancer
  • Glioblastoma
  • Colorectal cancer
  • Melanoma

Clinical interests also include molecularly selected therapy, neoadjuvant treatment, radiotherapy combinations, and personalized tumour profiling.

Neurology, Stroke, and Cognitive Disorders

Trials address acute ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis, migraine, cognitive impairment, delirium, and autism spectrum disorder, reflecting sustained interest in neurological function, neuroprotection, and symptom control.

  • Acute ischemic stroke
  • Multiple sclerosis
  • Amyotrophic lateral sclerosis
  • Chronic migraine
  • Delirium

Work in this area also covers neural plasticity, post-stroke recovery, and treatment of brain metastases and other central nervous system conditions.

Cardiovascular, Transplantation, and Perioperative Care

Research spans aortic stenosis, arrhythmic mitral valve prolapse, heart transplant, kidney transplantation, kidney failure, and univentricular congenital heart disease, with attention to graft function, rhythm disorders, and cardiovascular support.

  • Aortic stenosis
  • Heart transplant
  • Kidney transplantation
  • Arrhythmic mitral valve prolapse
  • Kidney failure

Additional themes include anticoagulation, hemodynamic management, postoperative delirium, and renal protection in transplant recipients.

Inflammatory, Rare, and Organ-Specific Diseases

The portfolio includes primary sclerosing cholangitis, juvenile idiopathic arthritis, granulomatous lymphocytic interstitial lung disease, venous malformation, frontal fibrosing alopecia, keratolytic winter erythema, and hydrocephalus, showing interest in rare and organ-specific disorders.

  • Primary sclerosing cholangitis
  • Juvenile idiopathic arthritis
  • Granulomatous lymphocytic interstitial lung disease
  • Venous malformation
  • Hydrocephalus

Other areas include ophthalmology, orthopaedics, infectious diseases, and maternal and neonatal care, alongside studies of pain and functional recovery.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Pyridoxine for Patients with Primary Sclerosing Cholangitis

    Not recruiting

    2 1 1
    Investigated drugs:
    Norway
  • Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +8
  • Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

    Not recruiting

    2 1
    Investigated drugs:
    Belgium Czechia France Greece Ireland Italy +4
  • Study on Theophylline for Improving Exercise Capacity in Adolescents with Univentricular Heart Disease and Fontan Circulation

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway
  • Study on Treating Keratolytic Winter Erythema in Adults Using Nitroxoline

    Not recruiting

    2 1 1
    Investigated diseases:
    Norway
  • Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma

    Not recruiting

    2 1 1
    Investigated drugs:
    Denmark Finland Norway Sweden